Interstitial Cystitis News and Research

RSS
Interstitial cystitis (IC) is a condition that results in recurring discomfort or pain in the bladder and the surrounding pelvic region. The symptoms vary from case to case and even in the same individual. People may experience mild discomfort, pressure, tenderness, or intense pain in the bladder and pelvic area. Symptoms may include an urgent need to urinate, a frequent need to urinate, or a combination of these symptoms. Pain may change in intensity as the bladder fills with urine or as it empties. Women’s symptoms often get worse during menstruation. They may sometimes experience pain during vaginal intercourse.
SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

SCS, PNS prove to be effective tools in treating chronic pain: NANS, ASIPP

MediciNova receives FDA approval to proceed with initial trial of ibudilast

MediciNova receives FDA approval to proceed with initial trial of ibudilast

National Health Information Resource Center honors Interstitial Cystitis Association for special publication

National Health Information Resource Center honors Interstitial Cystitis Association for special publication

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Article related to MN-166 mechanism of action included in PNAS USA

Article related to MN-166 mechanism of action included in PNAS USA

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

ICA hosts forum to improve quality of healthcare and lives of people with IC

ICA hosts forum to improve quality of healthcare and lives of people with IC

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova announces $15 million senior secured term loan with Oxford Finance

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Urigen Pharmaceuticals requests FDA meeting for advancing URG101 clinical program

Clinical utility and pharmacological action of MN-166 in treatment of MS

Clinical utility and pharmacological action of MN-166 in treatment of MS

Beaumont Hospital opens women's urology center

Beaumont Hospital opens women's urology center

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

MediciNova reports net loss of $5.9 million for 2009 fourth quarter

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

TTI granted exclusive worldwide rights to commercialize two immunology programs

TTI granted exclusive worldwide rights to commercialize two immunology programs

Clinical research study conducted for patients with IC/PBS

Clinical research study conducted for patients with IC/PBS

Results from three phase two studies show the effectiveness of Tanezumab

Results from three phase two studies show the effectiveness of Tanezumab

TTI enters into definitive license agreement with Biogen Idec

TTI enters into definitive license agreement with Biogen Idec

Findings suggest abuse is a risk factor for chronic headache

Findings suggest abuse is a risk factor for chronic headache

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

TARIS Biomedical completes Phase 1 study of its intravesical drug-device convergence system

TARIS Biomedical completes Phase 1 study of its intravesical drug-device convergence system